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Abstract
Background—Rabies is an acute fatal encephalitis caused by all members of the Lyssavirus 
genus. The first human rabies survivor without benefit of prior vaccination was reported from 
Milwaukee in 2005. We report a second unvaccinated patient who showed early recovery from 
rabies and then died accidentally during convalescence, providing an unparalleled opportunity to 
examine the histopathology as well as immune and virological correlates of early recovery from 
human rabies.
Methods—Case report, rapid fluorescent focus inhibition test, enzyme-linked immunosorbent 
assay, indirect and direct fluorescent antibody assays, reverse-transcriptase polymerase chain 
reaction, phylogenetic reconstruction, isolation in tissue culture, pathology and 
immunohistochemistry.
Results—The 9 year old died 76 days after presenting with rabies of vampire bat phylogeny 
transmitted by cat bite. Antibody response in serum and cerebrospinal fluid was robust and 
associated with severe cerebral edema. No rabies virus was cultured at autopsy. Rabies virus 
antigen was atypical in size and distribution. Rabies virus genome was present in neocortex but 
absent in brainstem.
Conclusions—Clinical recovery was associated with detection of neutralizing antibody and 
clearance of infectious rabies virus in the central nervous system by 76 days but not clearance of 
detectable viral subcomponents such as nucleoprotein antigen or RNA in brain.
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Rabies is an acute fatal encephalitis caused by all members of the Lyssavirus genus, 
including rabies virus (RABV). While vaccine preventable for over a century, RABVs 
remains the leading global zoonosis, killing more than 55,000 persons annually.1 The first 
human rabies survivor without benefit of prior vaccination was reported from Milwaukee in 
2005.2 We report a second unvaccinated patient who showed early recovery from rabies and 
then died accidentally during convalescence, providing an unparalleled opportunity to 
examine the histopathology as well as immune and virological correlates of early recovery 
from human rabies. These findings add to a small body of laboratory studies of human 
rabies that provide insights into the chronology of RABV–host interactions.3–7
MATERIALS AND METHODS
Detection of RABV-neutralizing Antibodies by the Rapid Fluorescent Focus Inhibition Test 
(RFFIT)
This cell culture–based microneutralization test assessed virus inhibition by serially diluted 
serum and cerebrospinal fluid (CSF) against a standardized amount of reference RABV 
(CVS-11, laboratory strain). The test was performed on serial (5-fold) dilutions of heat-
inactivated serum and CSF samples in 8-well LabTek chamber slides (Thermo Scientific, 
Waltham, MA) using mouse neuroblastoma (MNA) cell culture as described.8 The World 
Health Organization standard serum (2 IU/mL) was used for calibration.
Detection of RABV Antibodies by an Enzyme-linked Immunosorbent Assay (ELISA)
The Platelia Rabies II (Bio-Rad Laboratories, Hercules, CA) is a kit that detects 
glycoprotein G–binding antibodies in serum and CSF samples. ELISA plates were coated 
with purified RABV glycoprotein, and serial dilutions of serum and CSF were assayed. 
Titers of glycoprotein-binding antibodies were estimated based on a standard curve using 
reference serum according to the manufacturer’s instructions.9
Detection of Class-specific RABV-binding Antibodies by an Indirect Fluorescent Antibody 
(IFA) Assay
This assay detected CSF and serum antibodies binding to RABV structural proteins. A 
monolayer of MNA cells, infected with the CVS-11 RABV strain and fixed with acetone, 
was used as antigen. Serial dilutions of serum and CSF were placed on the fixed 4-well 
antigen-coated slides for antibody quantification. A secondary goat or rabbit anti-human IgG 
or IgM fluorescein isothiocyanate-labeled conjugates identified the presence of antibodies as 
described elsewhere.10
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Detection of RABV Antigens by Direct Fluorescent Antibody (DFA) in a Skin Biopsy
Horizontal and vertical planes of a skin biopsy, mounted in Tissue Freezing Medium 
(Triangle Biomedical Sciences, Durham, NC), were frozen and cut in 8-μm sections and 
DFA stained as described.11,12
Detection of RABV Nucleic Acid by a Heminested Reverse-transcription Polymerase Chain 
Reaction (RT-PCR)
This technique targeted the RABV nucleoprotein (N) gene in saliva, nuchal skin and brain 
tissues. Total RNA was extracted with the use of TRIZol reagent (Invitrogen, San Diego, 
CA) according to the manufacturer’s instructions. For maximum sensitivity, we did a 2-step 
primary RT-PCR with primer sets 001-550B, 550F-304 and 1066Fdeg-304 followed by a 
second round of heminested PCR reactions as follows: 001-550B product was reamplified 
with primers N7deg-550B; the 550F-304 PCR product was amplified with primers 
550F-1066deg reverse and 1066Fdeg-304 in separate reactions and the 1066Fdeg-304 PCR 
product was amplified with primers 1087Fdeg-304 and 504S-304 in separate reactions 
(Table 1).11,13,14 RT was performed for 90 minutes at 42°C followed by a 4°C hold. PCR 
conditions were as follows: 1 minute at 94°C followed by 40 cycles of 94°C for 30 seconds, 
37°C for 30 seconds and 72°C for 90 seconds, followed by 7-minute extension at 72°C. 
Amplicons were purified and subjected to direct sequencing according to the manufacturer’s 
instructions (ABI Prism Big dye terminator v1.1 ready reaction mix Cycle sequencing kit, 
and sequence analyzer 3023; Applied Biosystems, Foster City, CA).13,15
RABV Typing Using Sequence Analysis and Phylogenetic Reconstruction
Sequences newly generated during this study were submitted to GenBank for assignation of 
consecutive accession numbers JF693449–JF693484.
Viral gene sequences obtained from patient’s antemortem or postmortem samples were 
analyzed together with recent and historic RABV-positive samples obtained in Colombia 
and other countries in the United States (Table 2). Phylogenetic reconstructions were run 
with MEGA software v 5.0, using maximum-likelihood and neighbor-joining methods.16
RABV Isolation From Brain Tissues and Saliva in Cell Culture
Approximately 100–500 μL of saliva was used to prepare suspensions in 1000 μL of 
MEM-10% fetal calf serum. Additional washings of brain tissue sediment through 
resuspension and centrifugation at 500g were introduced. Aliquots of this inoculum (100–
400 μL) were incubated with a suspension of MNA cells (4–5 × 106). RABV presence was 
monitored in the LabTek slides at 24, 48, 72 and 96 hours using the DFA test as 
described.11,17 Supernatants were passaged serially to maximize detection of wildtype 
RABV.
Detection of RABV Antigens by the DFA Test
Brain touch impressions were examined for the presence of RABV antigens using the 
national standard protocol for rabies diagnosis in the United States, as described.12
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Detection of RABV Antigens by the Direct Rapid Immunohistochemistry (IHC) Test
The direct rapid IHC test was performed on fresh brain, brainstem, cerebellum and 
hippocampus, as described.18
Detection of RABV Antigens by IHC
Routine hematoxylin and eosin stains and IHC were performed on representative brain 
tissues as well as skin and salivary glands. Hematoxylin and eosin slides were evaluated for 
histopathology. IHC was performed using a colorimetric polymer-based indirect 
immunoalkaline phosphatase procedure as described.19
Case Report
On July 10, 2008, a 9-year-old girl was bitten by her unvaccinated cat in a southwestern 
rural area of Colombia, South America. The cat was then killed without laboratory testing 
for rabies. She was taken to the clinic 3 hours away, where the wounds were cleaned, tetanus 
vaccine given and antibiotics dispensed. Rabies vaccine and immune globulin were not 
available. On August 8, the girl developed fevers, headache, myalgia, vomiting and trouble 
swallowing. The next day, she showed alternating agitation and somnolence. On August 10, 
she was taken to the clinic and diagnosed with either meningitis or encephalitis. She was 
sent to a regional hospital and then to Hospital Universitario del Valle, in Cali, Colombia, by 
August 12.
At time of transfer, on the fourth day of illness [hospital day (HD) 3, based on admission to 
the first hospital], the patient was somnolent and salivating. Her temperature was 38°C, 
pulse 98/min, respirations 24/min and blood pressure of 97/66 mm Hg. She did not respond 
to commands, with eye opening and extensor posturing to pain. She had left hemiparesis and 
left gaze preference. Samples of saliva, serum, CSF and corneal impressions were sent to the 
National Institute of Health in Bogota, Colombia. White blood cells (WBCs) were 
4600/mm3 (60% neutrophils and 24% lymphocytes), hemoglobin 12.5 g/dL, platelets 
441,000/mm3 and C-reactive protein 200 μg/L. CSF showed 1 red blood cell, 233 WBC (4% 
neutrophils), glucose 71 mg/dL (serum 91 mg/dL) and protein 48 mg/dL. Chest radiograph 
(CXR) and computed tomography (CT) of the head were normal.
A meeting with hospital leadership, pediatricians, intensivists, infectious disease consultants, 
psychologists and the legal department was held. The decision was made to attempt 
treatment according to the Milwaukee Protocol adapted to local resources.20 After 
laboratory confirmation of rabies on HD6, therapy was initiated with ventilation, ketamine, 
midazolam, phenobarbital, thiopental, magnesium sulfate, amantadine, oral ribavirin, 
sublingual interferon alpha and medroxyprogesterone. The case was discussed with experts 
at the Centers for Disease Control and Prevention, Atlanta, GA, and the Medical College of 
Wisconsin; ribavirin and interferon were stopped and barbiturates tapered.
The patient became unstable on HD7, with anisocoria, hypertension, bradycardia with 
extrasystoles and metabolic acidosis. Serum sodium was 149 mEq/L. Lidocaine, mannitol 
and hypertonic saline were administered and the patient improved. Repeat CT was normal. 
The patient became hypotensive and bradycardic, requiring plasma, plasma expanders and 2 
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boluses of epinephrine. Bispectral index monitoring [a simplified form of 
electroencephalogram (EEG) used in anesthesiology] showed a decline in scores of 58 to 21 
over the next 4 days. A urinary tract infection with resistant Escherichia coli was treated. 
CSF on HD10 showed 154 WBC, 70 red blood cells, protein 146 mg/dl and glucose 48 
mg/dl. Serum prolactin, used to monitor central nervous system (CNS) dopamine 
production, was 5.61 ng/mL (normal: 3.25–29.1). Sapropterin and vitamin C were 
initiated.21 EEG on HD11 showed reduced activity on the right, with alpha rhythm 
predominance. CSF on HD12 showed 133 WBC, 5 red blood cells, protein 203, glucose 130 
and lactate dehydrogenase 272 IU/L. On HD13, the bispectral index score abruptly 
decreased to 7, and sedation was tapered; bispectral index score increased to 25 with 
increased blood pressure. Serum sodium was 136. Pupils remained symmetric and reactive.
On HD14, signs of recovery were first noted. She showed fluttering of eyelids and return of 
corneal, cough and ankle reflexes. In contrast, CT showed diffuse cerebral edema without 
midline shift and hypodensity in the left basal ganglia. Mannitol and hypertonic saline were 
administered. Neurosurgeons advised against placing an intraventricular drain because of a 
concurrent outbreak of bacterially infected ventricular shunts. On HD16, the patient 
breathed spontaneously. Sedation was increased to control agitation. Patellar and ankle 
reflexes were brisk. EEG showed response to stimuli, and recovery of right-sided activity 
but diminution in the fronto-central-parietal areas bilaterally.
HD17 to HD32 were characterized by 3 episodes of anisocoria and hypertension, treated 
with hypertonic saline, mannitol and thiopental. Serum sodium concentrations were 
extremely labile, ranging from 129 to 156, and confounded by runs of hypertonic saline and 
use of diuretics. CT on HD17 showed worsening of left cortical edema with obliteration of 
the lateral ventricle and marked edema of the basal ganglia. CT angiography on HD22 
showed effacement of the cortical gyri, transtentorial herniation with compression of the 
posterior cerebral artery and possible left occipital lobe infarction. There was no venous 
thrombosis. The patient was markedly acidotic (pH 7.06 with a pCO2 of 105) on return from 
CT. On HD31, CT showed improved edema, with a left occipital hematoma. On HD32, a 
tracheostomy was performed. During HD33 to HD51, serum sodium concentrations were 
stabilized with enteral sodium supplementation. She had frequent episodes of hypothermia 
associated with bradycardia.
On HD 39, CT showed less edema, with irregular hypodensities in frontal and occipital 
lobes and basal ganglia. Sedation was discontinued. The next day, the patient breathed 
independently, had equal and reactive pupils and moved her head to avoid light in her eyes. 
She spontaneously moved her legs and had increased reflexes in arms and legs. By HD44, 
she opened her mouth, moved her tongue and sucked on swabs. On HD45, she turned her 
head to voice and showed subtle arm movements. She was treated for a urinary tract 
infection.
She was weaned off the ventilator on HD47. By HD48, she appeared more awake, sucked 
on a candy and moved 2 fingers on her left hand to command. There was eye deviation to 
the left. On HD50, based on low CSF tetrahydrobiopterin and monoamine neurotransmitter 
concentrations, sapropterin was restarted with gradual increase to 20 mg/kg/d. On HD51, 
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she clearly preferred the voices of her mother and her regular nurse to others, also becoming 
emotional when she heard them. When presented with her mother’s face, she increased the 
frequency of her mouth movements.
On HD55, neurology consultation documented an awake patient with spontaneous 
movements of head, legs and left hand, strength 3/5. She did not follow commands 
consistently. She did not blink to a loud noise. Right eye was deviated outward; left eye had 
mesial and lateral paresis. In a seated position, she did not support her head and did not 
follow commands. The following day, she moved her right hand and both shoulders. Sodium 
supplementation was discontinued. On HD58, speech therapy certified adequate swallowing 
and protection of the airway. Sapropterin dosing reached therapeutic range. EEG showed 
greater activity on the left, reacting to stimuli, with theta rhythm. Over several days, she was 
somnolent correlating with serum sodium of 134, with improvements in alertness with 
serum sodium concentrations in the 140s, so oral supplementation at 9 mg/kg/d was 
restarted.
On HD61, the patient was removed from isolation. Visual-evoked responses were negative. 
Auditory-evoked responses showed decreased amplitudes, with normal brainstem and spiral 
ganglion cell responses. Magnetic resonance imaging on HD62 showed increased T2 signal 
in parieto-occipital regions, caudate and putamen, T1 changes in caudate nuclei and left 
temporo-occipital infarct, with mildly enlarged ventricles and cerebellar atrophy. Cervical 
cord was normal. On HD63, she extended her arms on stimulation of the arms and face and 
controlled her head position. On HD66, she was discharged from the intensive care unit.
On HD70, she developed fever, difficulty breathing, desaturations and rhonchi and produced 
purulent sputum. She was pale and listless. WBC was 8300 with 80% neutrophils. C-
reactive protein was 224 μg/L. CXR showed right basilar alveolar infiltrates. The patient 
was moved to the intensive care unit and given diuretics and antimicrobials. On HD72, she 
became hypertensive, tachycardic, with serum sodium greater than 200 mEq/L. Vasopressin 
test excluded central diabetes insipidus. The patient required 70% inspired oxygen 
concentration. CXR showed worsening infiltrates. She was intubated. She was given free 
water, and her serum sodium decreased by 28 mEq/L over 24 hours. On HD74, she became 
hypotensive. Attempts to place central lines resulted in bilateral pneumothoraces with 
hypotension and oxygen desaturations of 50% for over 2 hours. The patient was placed on 
dopamine and nor-epinephrine drips and transfused. On HD75, cardiac echo showed 




Humoral Immune Response—At the National Institute of Health in Bogota, Colombia, 
RABV antiglycoprotein (G) antibodies were evaluated using a commercial ELISA kit 
(Platelia Rabies II). A titer of 0.5 IU/mL was detected in serum 4 days after onset of 
symptoms (HD3), while no antibody was detected in CSF (Fig. 1A, B). In a symptomatic, 
unvaccinated patient, detection of serum antibodies is diagnostic of rabies. RFFIT (detecting 
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RABV-neutralizing antibody) and IFA tests (detecting antibodies that bind to various RABV 
proteins, predominantly to the abundant nucleoprotein), performed at Centers for Disease 
Control and Prevention a week later using the same serum and CSF aliquots, detected 
neutralizing activity and RABV-binding IgM and IgG in both serum and CSF (Fig. 1A, B). 
Titers in serum and CSF then rapidly rose, with the maximum humoral immune response in 
CSF and serum at days 41 (HD40) and 46 (HD45) after disease onset, respectively. While 
showing comparable sensitivity at lower concentrations of anti-G antibodies, the ELISA 
became asymptotic around 14 IU/mL, while RFFIT titers were at least 10-fold higher. IFA 
titers of RABV-binding antibody paralleled RFFIT titers in this individual. The IgG titer in 
brain tissue was about 10-fold higher than the last CSF sample (Fig. 1B).
Detection of RABV Antigens by DFA Test—Corneal impressions taken at time of 
transfer to the tertiary hospital (HD3) and in a biopsy of nuchal skin taken 13 days (HD12) 
after the onset of symptoms were negative for RABV antigens.
Detection of RABV Nucleic Acids—By RT-PCR, RABV RNA (N gene) was detected 
in saliva only on HD14 and HD18. RABV RNA was absent in the only skin biopsy sample 
available at HD14 (Table 3).
The sequence of viral N gene obtained from the patient’s saliva presented the highest 
nucleotide similarity (99.2%) with sequences of a RABV variant circulating in vampire bats 
near the patient’s hometown (Fig. 2 and Table 2).
Postmortem Results
RABV Isolation Attempts—No RABV was isolated from brain samples including brain 
stem, cerebellum, hippocampus, temporal and occipital lobes as well as from saliva after 3 
passages of 15 days in MNA cells. Intracerebral isolation in suckling mice was not 
attempted because susceptibility of MNA cells to RABV is equal or greater than 
susceptibility of suckling mice at the contributing rabies reference center.
Detection of RABV Antigens—Samples including brain stem, cerebellum, 
hippocampus, temporal and occipital lobes, kidney, liver, salivary glands, skin and saliva 
were available at autopsy. RABV antigens were detected by DFA in the hippocampus. Scant 
and atypically distributed intracytoplasmic inclusions with sizes ranging from 0.1 to 1 μm 
were observed in some sections of the brain stem, temporal and occipital lobes but not in 
other sections. No RABV antigens were detected in an autopsy skin specimen. Other tissues 
were not tested by DFA.
Direct rapid IHC test was performed on the same material subjected to DFA. Results by this 
technique were inconclusive because only a limited number of scattered inclusions, different 
in distribution and intensity from the positive control samples, were observed. Human brain 
without rabies showed no inclusions.
Histopathology—Microscopic pathological examination of CNS specimens showed 
necrosis, gliosis and inflammatory infiltrates in parenchyma and perivascular space. The 
inflammatory infiltrates were mainly composed of lymphocytes and macrophages. No 
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significant pathology was observed in skin and salivary gland. No RABV antigens were 
detected in any specimens tested by IHC (Fig. 3).
Detection of RABV Nucleic Acid—RABV RNA was detected by both primary and 
heminested RT-PCR in cerebellum, hippocampus and brain cortex (temporal and occipital 
regions), but not in brain stem. RABV RNA was not found in the kidneys, lungs, skin 
biopsy, salivary glands or saliva of the patient. RT-PCR amplicons from brain tissues were 
sequenced and compared among each other and with sequences obtained initially from the 
saliva samples at days HD12 and HD16. All were 100% identical to each other.
DISCUSSION
This patient was the second known human to show recovery from rabies without benefit of 
prior vaccination, thereby establishing that Homo sapiens can recover from wildtype rabies. 
Many other species also produce occasional rabies survivors.22 After the first report of 
survival after human rabies without prior immunization, operational definitions of survival, 
therapeutic futility and lack of transmissibility (for infection control) were developed.2,23 
Survival was defined in 2005 by 4 a priori criteria: (1) rabies diagnosis confirmed by a 
rabies reference laboratory, (2) absence of detectable RABV in saliva and/or skin, (3) 
concurrent development of neutralizing antibodies to RABV and (4) discharge of the 
convalescent patient from the intensive care unit. This patient met all 4 criteria for survival 
from rabies. A threshold duration of survival after onset of rabies was not considered as an 
ad hoc criterion for survival in 2005 because the 90th percentile for survival with rabies in 
the United States was only 18 days, and there were fewer than 10 patients over a 40-year 
span with rabies (all vaccine recipients) who had survived beyond 30 days. Our definition of 
survival is in retrospect problematic because our patient died 76 days after hospitalization, 
but not as a clear consequence of RABV infection. Whether to call our patient a survivor is 
debatable. Given the rarity of any survival from rabies, alternative statistical approaches 
quantifying duration of survival may be preferred.24 Conversely to having met ad hoc 
criteria for survival, our patient never met ad hoc criteria for therapeutic futility, which were 
defined in 2007.6,25 This patient had CSF protein levels greater than 200 mg/dL, which is 1 
of 5 ad hoc criteria for therapeutic futility. The other 4 criteria, such as, fixed pupils, 
isoelectric EEG, diabetes insipidus and CSF lactate greater than 4.0 mM, were not present 
concurrently. This patient also met ad hoc criteria for discontinuation of isolation beyond 
standard precautions.2 Droplet isolation was discontinued when 3 saliva samples after HD16 
were negative for RABV nucleic acid by heminested RT-PCR, and the patient had 
demonstrated the presence of RABV-neutralizing antibodies indicative of adequate humoral 
response.
This patient showed initial clinical improvement on HD14, at a time when both systemic and 
CSF concentrations of neutralizing antibody likely exceeded 1.0 IU/mL. Neurological 
recovery in this patient was faster than in the first vaccine-naive survivor.2 Her course was 
then complicated by hyponatremia and refractory cerebral edema, causing an occipital 
stroke. It is almost certain that she would have had significant neurological sequelae, 
including blindness, had she survived. After partial resolution of her cerebral edema, she 
followed commands inconstantly and showed preference for familiar voices and a passion 
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for sweets. She breathed independently, swallowed well, had head control and was regaining 
use of her 4 extremities, but was not verbal at the time of her premature demise. From over 
140 case reports of rabies in the peer-reviewed English literature, we are aware of only one 
other report of human rabies describing recovery of function during medical care of a 
nonsurvivor, and that patient was treated similarly to our patient but died of renal failure.3 
The referenced patient did not meet our a priori definition of survival and was not reported 
as a survivor. For a nonsurvivor to regain any neurological function is otherwise 
unprecedented in the medical literature.
Four rabies vaccine-naive patients have now putatively survived rabies.2,26,27 Confirmation 
of the diagnosis of the 2011 India survivor is uncertain while the diagnosis of the California 
and Texas survivors relied on immunofluorescence assays that have been challenged.28 The 
2011 California survivor did not mount a RABV-neutralizing antibody response.26 The 
putative rabies survivor in Texas showed mild symptoms, like the India survivor, and did 
not show consistent RABV-neutralizing antibody in serum or CSF, like the California 
survivor.29 There is considerable debate about the California and Texas cases, but there is no 
acceptable alternative hypothesis. Testing of the California patient for autoimmune disease 
was extensive. High-volume reference laboratories associated with the California 
Encephalitis Project and the Centers for Disease Control and Prevention do not encounter 
positive IFA results for RABV in other encephalitis cases referred for diagnosis, and there 
are no other known Lyssaviruses in the United States that cross-react by IFA with RABV. 
However, a new vesiculovirus has been reported in North American bats that might 
theoretically cross-react.1 The novel vesiculovirus has not been cultivated. Our report 
provides more robust laboratory proof of concept that rabies vaccine-naive humans may 
survive clinically severe rabies. Individual case reports are unlikely to elucidate mechanisms 
associated with survival but may generate testable hypotheses for animal models or 
therapeutic trials.
The dynamics of RABV clearance in humans are becoming clearer. Partial to complete loss 
of cultivable virus has been reported in brain 11–22 days after detection of serum 
neutralizing antibodies >1.0 IU/mL, while RABV antigen was still detectable in 3 of 4 
instances.4,7,30,31 In this patient, 67 days after developing a CSF antibody response >1.0 
IU/mL, RABV RNA and antigen were still detectable, but isolation of infectious RABV 
failed. (The failure to detect RABV antigen by IHC while fluorescent antibodies delineated 
intracytoplasmic inclusions likely relates to the logarithmically higher signal provided by 
fluorescent probes over conventional tissue stains.) Clearance of RABV antigen (and 
cultivable virus) was complete in the brain of a patient 127 days after exposure to high titers 
of neutralizing antibody.5 In mice surviving wildtype rabies, RABV antigen was present for 
up to 30 days; in a ferret that survived wildtype rabies, RABV antigen was undetectable 
after 76 days.32,33 RABV antigen was present 5 days longer than infectious virus and viral 
RNA in murine models of fixed (laboratory adapted) RABV infection.34 These aggregate 
observations in mice and man support the concept that clinical recovery occurs 
commensurate with RABV-specific antibody production and loss of infectious virus, while 
clearance of RABV antigen and RNA from brain takes several weeks after first detection of 
RABV-neutralizing antibodies.
Caicedo et al. Page 9













In typical human rabies cases, intracytoplasmic inclusions are homogeneously distributed 
throughout brain stem, hippocampus, cerebellum and several other regions of the brain, 
ranging from 0.25 to 27 μm in size. In this patient, intracytoplasmic inclusions were smaller 
(0.1–1 μm) and similar to those found in previously vaccinated rabid animals. Changes in 
intracytoplasmic inclusion size may therefore provide an additional immunological marker 
of RABV clearance.
In retrospect, this patient was the first of 3 patients with bat-transmitted rabies who 
developed severe cerebral edema temporally associated with CSF RABV-neutralizing 
antibody titers at least 10-fold higher than those of the initial survivor (personal 
communications, G. Sanchez, Lima, Peru; C. Zahlouth, Brasilia, Brazil). A fourth patient, 
undergoing postexposure prophylaxis at time of onset, had a similar high range of CSF titers 
without developing severe cerebral edema (personal communication, G. Henriques, Recife, 
Brazil). In contrast to the disease caused by bat-derived RABV, severe cerebral edema was 
rarely encountered during the immune response to dog-transmitted RABV (unpublished 
data, RW). Peak CSF titers of RABV-neutralizing antibody in 18 rabies patients that 
acquired the infection from dogs were, with 1 exception, at least 100-fold lower than they 
were in this patient. One patient bitten by a dog, who completed postexposure prophylaxis 
before onset of rabies, developed similarly high titers in CSF and survived; we do not know 
whether cerebral edema occurred, but outcome was poor (personal communication, G. Al-
Sulaiti, Doha, Qatar.) We hypothesize a possible dose relationship of CNS antibody 
response in causing cerebral edema, although the vaccinated Brazilian and Qatari survivors 
suggest that more complex mechanisms may be involved. Cerebral edema in rabies is almost 
never related to loss of integrity of the blood-brain barrier, so other mechanisms for cerebral 
edema must be considered.35–38 Antibody-mediated clearance may involve intracellular 
antibodies to the RABV, so cytoplasmic interaction of antibodies and virus subparticles may 
cause isotonic volume expansion.39 N-acetylaspartate, secreted by neurons to reduce cellular 
volume, is markedly elevated in CSF in rabies, supporting a possible disorder of volume 
regulation by neurons.40 Cerebral edema in our patient was complicated by what appeared to 
be hyponatremia from renal salt wasting, but salt wasting could not be conclusively 
diagnosed in this critically ill patient because of concomitant use of diuretics and sodium 
supplementation. Sympathetic innervation of the kidneys controls natriuresis, while RABV 
has been detected in proximal tubular cells or urinary sediment and associated with 
glycosuria, so renal salt wasting is biologically plausible by 2 mechanisms: dysautonomia 
and renal tubular dysfunction.4,19,41–43 Both cerebral edema and salt wasting lasted weeks.43 
Management of hyponatremia in this patient was facilitated by use of enteral sodium 
supplementation. Based on further experience with other rabies patients, we recommend 
mineralocorticoids for prophylaxis and treatment of hyponatremia, salt wasting and cerebral 
vasospasm.23,44,45
This case identifies potential clinical differences in rabies of bat versus carnivore phylogeny 
that affect medical management. In this patient, early clinical recovery was associated with 
detection of neutralizing antibody and clearance of infectious (cultivable) RABV in the CNS 
by 76 days, but not clearance of detectable viral subcomponents such as nucleoprotein 
antigen or RNA in brain.
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A) Anti-rabies virus antibody kinetics in serum and CSF, monitored by ELISA and RFFIT. 
Increasing humoral immune response was elicited in both CSF and serum. RFFIT detected 
earlier and higher antibody titers in CSF and serum compared with ELISA. Timing of first 
detection of cerebral edema and stroke are illustrated. B) Anti-rabies virus class-specific 
antibody kinetics in serum and CSF, monitored by IFA. IgG class antibodies were detected 
in increasing titers in both sera and CSF, occurring in higher titers than IgM antibodies. 
Humoral immune responses tend to be higher in serum than in CSF.
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A) Phylogenetic relationships among 51 selected RABV isolates from Colombia and the 
United States 1985–2008. Neighbor joining with a maximum composite likelihood 
nucleotide substitution model was used for the phylogenetic reconstruction. The significance 
of each clade was estimated by a bootstrap algorithm applying 1000 iterations. Numbers at 
nodes indicate bootstrap values greater than 60%. The Lyssavirus species Duvenhage virus 
(DUVV) and European Bat Lyssavirus 2 (EBL-2) were included as outgroup. B) 
Geographical location of selected rabies isolates in Colombia 1994–2008. Circle A shows 
the location of patient case (H04/08). Conventions show host and genetic lineage for each 
isolate color coded matching their respective branches in the phylogenetic reconstruction.
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Postmortem RABV-specific immunohistochemistry test in brain stem (left column) and 
cerebellum (right column). A), B) Tissues of the patient addressed in this study where 
absence of rabies components is observed. Some histopathological findings included 
parenchymal necrosis, gliosis and inflammatory infiltrates in parenchyma and perivascular 
space. No prominent intracytoplasmic inclusion bodies were seen. C), D) Positive controls 
from a rabies-positive human brain obtained from the archive. Arrows indicate specific 
intracytoplasmic rabies virus antigen stained in red. All cell nuclei are stained in navy blue. 
E), F) Negative controls from a human brain confirmed negative for rabies.
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TABLE 1
Primers Detection of Rabies Virus by Polymerase Chain Reaction
Designation ID
Broadly Reactive or Degenerate Primers
Orientation Genome Position* Sequence Reference
001 Forward 1–16 ACGCTTAACGAMAAA 13
550 F† Forward 647–666 ATGTGYGCTAAYTGGAGYAC 13 †
550B Reverse 647–666 GTRCTCCARTTAGCRCACAT 13
1087Sdeg Forward 1157–1173 GAGAARGAACTTCARGA 11
1066 deg F Forward 1136–1155 GARAGAAGATTCTTCAGRGA 11
1066deg B† Reverse 1136–1155 TCYCTGAAGAATCTTCTYTC 11†
304‡ Reverse 1514–1533 TTGACGAAGATCTTGCTCAT 14
504S‡ Forward 1296–1312 TCATGATGAATGGAGGT 11
*
According to the full genome sequence of the fixed rabies virus strain, SAD B19 (Conzelmann et al. Molecular cloning and complete nucleotide 




Reverse complement of a published primer.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pediatr Infect Dis J. Author manuscript; available in PMC 2016 March 28.
